Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
2019 · Orphanet Journal of Rare Diseases · 77 citations
https://doi.org/10.1186/s13023-019-1012-x
Y
Ying Zhou
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
183
Papers
2.0K
Citations
26
h-index
60
i10-index
Ying Zhou is an academic researcher from Tongji University. The author has contributed to research in topics: Cancer, Lipids, and Metabolism & Prostate Cancer Treatment and Research & Antibiotics Pharmacokinetics and Efficacy. The author has an h-index of 26, co-authored 156 publications.
ORCID: 0000-0003-4440-5192Papers by this author
worksPrognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis
2019 · Breast Cancer Research and Treatment · 40 citations
https://doi.org/10.1007/s10549-019-05421-7
Development of a Population Pharmacokinetic Model of Vancomycin and its Application in Chinese Geriatric Patients with Pulmonary Infections
2018 · European Journal of Drug Metabolism and Pharmacokinetics · 26 citations
https://doi.org/10.1007/s13318-018-0534-2
Label-free single-cell protein quantification using a drop-based mix-and-read system
2015 · Scientific Reports · 25 citations
https://doi.org/10.1038/srep12756
DNA methylome profiling reveals epigenetic regulation of lipoprotein-associated phospholipase A2 in human vulnerable atherosclerotic plaque
2021 · Clinical Epigenetics · 23 citations
https://doi.org/10.1186/s13148-021-01152-z
Urinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse Event Reporting System
2023 · Expert Opinion on Drug Safety · 21 citations
https://doi.org/10.1080/14740338.2023.2288897
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat